All In Biotech

Free tool

FAERS Monitor: Readyprep Chg

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 207964 or its brand name (Readyprep Chg, Chlorhexidine Gluconate). Reports on generic versions are filed under their own applications.

Reports

66

Serious

37

56% of reports

Hospitalization

6

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • rash20
  • skin reaction12
  • erythema9
  • pruritus4
  • skin irritation4
  • sepsis3
  • burkholderia infection2
  • eye irritation2
  • hypersensitivity2
  • pain2
  • sputum culture positive2
  • ageusia1
  • alopecia1
  • anosmia1
  • application site discomfort1

Reports by year received

View as table
YearReports
20163
20174
20192
20201
20215
20221
202319
202410
202512
20269

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,093 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
burkholderia infection27876.61977.58,645
sputum culture positive2787.7200.9881
skin reactionSignal12271.7162.82,970
application site discomfort1177.525.443
skin irritationSignal427.810.879
anosmia122.03.15
rashSignal2014.610.1245
erythemaSignal914.07.697
ageusia112.81.82
eye irritation211.12.810
sepsisSignal38.62.813
hypersensitivity23.40.91
pruritusSignal43.31.34
alopecia11.60.20
pain21.00.30

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.